ClinicalTrials.gg
RecruitingNCT05163197TPLAforPCaUpdated Dec 20, 2021

Transperineal Laser Ablation Treatment (TPLA) for Prostate Cancer (PCa) Registry

An observational study in Prostate Cancer, sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). Recruiting at 1 site in Netherlands. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-12-20.

Sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Observational

How we know

From the registry’s dates

  • Started Oct 2021; still recruiting 5 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Prostatic Neoplasms by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) — 2 open to participants now, 3 under way, none of them phase 3. Prostatic Neoplasms · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA).

Started
2021
with 1 other
Observational
2 of 10
1 open now
Registered
7th of 10
by date

Among the 10 studies in Prostatic Neoplasms by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), this one is one of 2 that started in 2021, is one of 2 observational ones, and was the 7th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

2 of the 10 studies in Prostatic Neoplasms by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) are open now, in 1 country. Recruiting first, the newest first:

  • Not yet recruitingNCT06974539
    TULIP ReTrain Study

    Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Sites in Netherlands

    Ages 18+ · Men only

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Prostatic Neoplasms by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), or all of them as a file.
02

Study summary

Rationale: Transperineal laser ablation (TPLA) treatment for prostate cancer (PCa) is a minimal invasive focal therapy technique studied worldwide to determine its efficacy. In pilot studies it has shown to be a safe and feasible technique and it has potential to preserve continence and potency over current standard radical therapies. However, (long-term) treatment outcomes of TPLA for PCa remain largely unknown. The aim of this international retrospective registry is to collect and combine data on patients treated TPLA for PCa in order to provide data on safety, feasibility, functional and oncological outcomes.

Objective: To assess safety and feasibility of TPLA for PCa, to assess functional and oncological outcomes of TPLA for PCa and to determine baseline patient characteristics in a multicentre cohort.

Study design: This is an international, retrospective observational registry in which data is recorded of patients who have been treated with TPLA for PCa.

Study population: Male patients treated with TPLA for PCa. Main study parameters/endpoints: The primary endpoint of this registry is oncological outcomes of TPLA for PCa. Secondary endpoints are safety, feasibility and functional outcomes of TPLA for PCa.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • Laser Ablation
  • Minimal invasive
  • Focal therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The registry population comprises those patients that have been treated with TPLA for PCa.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male, histological-confirmed disease of localized prostate cancer, TPLA treatment for PCa is performed

Exclusion criteria

Exclusion Criteria:

  • Age \< 18 years
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Interventions

  • ProcedureTransperineal Laser Ablation of Prostate Cancer

    Minimal invasive transperineal laser ablation treatment for prostate cancer

    Also known as: Soractelite treatment, Echolaser X4

06

What researchers measure

Primary outcomes

  1. Oncological control

    Oncological control is defined as: a PSA \<=2.0ng/mL than initial PSA and/or no residual tumor or other lesion suspicious for prostate cancer on magnetic resonance imaging and/or no gleason score upgrading on re-biopsy and/or no clinical up-staging of prostate cancer T-stage

    Time frame: 12 months

Secondary outcomes

  1. Continence rate

    Continence is assessed by usage of number of pads per day, and 0-1 pad per day usage is defined as continent.

    Time frame: 12 months

  2. Potency rate

    Potency is defined as erectile function sufficient for sexual intercourse, with or without medical aid

    Time frame: 12 months

  3. Urinary flow

    Urinary flow is assessed by peak urinary flow (mL/s) and residual urine (mL). The higher the peak urinary flow and the lower the residual urine, the better the urinary flow.

    Time frame: 12 months

  4. PROM regarding voiding

    International Prostate Symptom Score (IPSS) is used to determine functional outcome regarding voiding. IPSS is on a score of 0 to 35, and the higher the score the worse the outcome.

    Time frame: 12 months

  5. PROM regarding erectile function

    International Index of Erectile Function (IIEF-5) is used to determine erectile function based on a validated questionnaire. IIEF-5 is on a scale of 5 to 25, and the higher the score the better the outcome.

    Time frame: 12 months

  6. Safety of TPLA for PCa

    Safety is defined as 10% or less CTCAE (version 5) grade 3 and no CTCAE grade 4 or 5

    Time frame: Up to 12 weeks

  7. Feasibility of TPLA for PCa

    Feasibility is assessed by amount of machine failures perioperatively of TPLA and hospital duration (hours) directly after TPLA.

    Time frame: Up to 4 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2021 (actual). Primary completion is estimated for Oct 2026, 60 months after the start.

Of 542 non-industry observational studies under Prostatic Neoplasms, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 162. This study's planned 60 months is below that.

Counting every sponsor, half of 651 studies reached it within 60 months; a quarter within 28 and three quarters within 141.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2021
First posted
Dec 20, 2021
StartActual
Oct 1, 2021
Primary completionEst.
Oct 1, 2026
CompletionEst.
Oct 1, 2027
Last update
Dec 20, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 20, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05163197
Responsible party
Prof.dr. H.P. Beerlage (Professor, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)) — Principal investigator
First posted
Dec 20, 2021
Start date
Oct 1, 2021
Primary completion
Oct 1, 2026 (estimated)
Completion
Oct 1, 2027 (estimated)
Last update
Dec 20, 2021

Study contacts

L. A. van Riel, MD
Contact
l.a.vanriel@amsterdamumc.nl
+31 6 50 06 30 94
J. R. Oddens, MD, PhD
Contact
j.r.oddens@amsterdamumc.nl
+31 6 50 06 30 94
J. R. Oddens, MD, PhD
principal investigator · Principal Investigator

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion